No Detail Found!

Assessment of Critical Quality Attributes of Budesonide and Formoterol Fumarate Dihydrate in Dry Powder Inhalers Marketed in Pakistan

Author(s)
Affan Ali Faculty of Pharmacy, Ziauddin University, Link Road Campus, Education City, Karachi, Pakistan.
Adeel Arsalan Faculty of Pharmacy, Ziauddin University, Link Road Campus, Education City, Karachi, Pakistan.
Saif ur Rehman Khattak Central Drugs Laboratory, Karachi, Pakistan.
Mirza Tasawer Baig Faculty of Pharmacy, Ziauddin University, Link Road Campus, Education City, Karachi, Pakistan.
Abstract
Summary: Dry powder inhalers (DPIs) have been well established and recognized for the delivery to the lungs. It provides better drug stability, less irritable, easy to use with deep penetration of drugs in the lungs. Budesonide (BDS) and formoterol fumarate dihydrate (FFD) indicated in pulmonary diseases. The main aim of the study is to evaluate BDS, FFD and their marketed DPIs product in Pakistan were compare in quality and performance with the reference product. The particle size distribution and aerodynamic characterization were analyzed by laser diffraction and multi stage liquid impinger, respectively. The particle density and delivered dose uniformity were also determined. HPLC was also used for the qualitative and quantitative estimation of BDS and FFD along with its marketed products. Laser diffraction particle size analyzer revealed Dv50 53.27 to 56.34 µm having surface area 1815 to 2304 cm3/g. The percentages of emitted dose (%ED) and fine particle fraction (%FPF) was found 98.19 to 99.23% and 31.57 to 34.87%, respectively. The mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) were calculated 2.62 to 2.89 µm and 1.99 to 2.54, correspondingly. The quantitative assay of BDS and FFD in all the commercial DPIs and reference product were well within the pharmacopeial limit i.e. 97.26 to 101.36%. The average of ten units results of delivered dose uniformity for BSD and FFD were also found in the range i.e. 97.97 to 103.19% and 98.48 to 104.41 %, respectively. The results of evaluation of parameters of DPIs like Dv50, %ED, %FPF, MMAD, GSD has shown compliance with the pharmacopeial standards. It is concluded that the all DPIs of BDS/FFD marketed in Pakistan has revealed conformance with the standard of pharmacopoeia and meet the requirements of drug regulatory authority of Pakistan.
Publication Details
Page(s) 425-434
Published Journal: Journal of Chemical Society of Pakistan, Volume: 46, Issue: 5, Year: 2024

Request the full text from PASTIC

Keywords
Budesonide, Formoterol Fumarate Dihydrate, Dry Powder Inhalers, Physical Characterization., Marketed
References
J. B. Soriano P. J.,Kendrick K. R.,Paulson K. R. .2020 .Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Respir. Med, 8(585) : .
Tiotiu A. I.,Novakova P.,Nedeva D.,ChongNeto H. J. .2020 .Impact of air pollution on asthma outcomes. Int. J. Environ. Res. Public Health, 17(6212) : .
Asthma Report Global .2024 .. Pakistan%20is%20the%20world's%20fifth,s uspected%20to%20suffer%20from%20asthma (accessed on March 23, : .
Khan M. A. .2022 .Monthly and seasonal prevalence of asthma and chronic obstructive pulmonary disease in the district Dera Ismail Khan. , 16(63) : .
5. H. A. M. Kerstjens J. W.,Upham I. A.,Yang I. A. .2019 .Airway pharmacology: treatment options and algorithms to treat patients with chronic obstructive pulmonary disease. J. Thorac. Dis., 11(S2200) : .
Boardman C.,Chachi L.,Gavrila A.,Keenan C. R. .2014 .Mechanisms of glucocorticoid action and insensitivity in airways disease. Pulm. Pharmacol. Ther., 29(129) : .
K. M. Beeh P.,Kuna M.,Corradi I.,Viaud I. .2021 .Comparison of dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone. dipropionate/formoterol fumarate/glycopyrronium in patients with copd: the tri-d randomized controlled trial. Int. J. Chron. Obstruct. Pulmon. Dis., 16(79) : .
Ramadan W. H.,Sarkis A. T .2017 .Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study. Chron Respir Dis, 14(309) : .
Patton J. S.,Byron P. R. .2007 .Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov., 6, (67) : .
Sahane S.,Nikhar A.,Bhaskaran S.,Mundhada D. .2012 .Dry powder inhaler: an advance technique for pulmonary drug delivery system. Int. J. Pharm. Chem. Sci., 1(1376) : .
Lee H. J.,Kang J. H.,Lee H. G.,Kim D.W. .2016 .Preparation and physicochemical characterization of spray-dried and jet-milled microparticles containing bosentan hydrate for dry powder inhalation aerosols. Drug Des. Dev, 10(4017) : .
Chaurasia B.,Zhao Y. Y. .2021 .Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics, 13(31) : .
Maloney S. E.,Mecham J. B.,Hickey A. J. .2023 .Performance Testing for Dry Powder Inhaler Products: Towards Clinical Relevance. KONA Powder Part. , 40(172) : .
J. Ignjatovic T.,Sustersic A.,Bodic A. .2021 .comparative assessment of in vitro and in silico methods for aerodynamic characterization of powders for inhalation. Pharmaceutics, 13 : .
M. Dhandayuthapani K.,Uma M.,Shivashankar N. K.,Fuloria N. K. .2022 .A study of formoterol plus budesonide combination in asthma control and symptom management of moderate to severe asthmatics in northern parts of Tamilnadu. J. Pharm. Negat. Results, 13(Suppl) : 8426-35.
Taşkın D.,Erensoy G.,Sungur S. .2016 .A validated spectrophotometric method for determination of formoterol fumarate dihydrate in bulk and dosage form using methyl orange as ion pair reagent. Marmara Pharm. J., 20 : 275-279.
A. J. Mali A. P.,Pawar R. N.,Purohit R. N. .2014 .Development of budesonide loaded biopolymer based dry powder inhaler: optimization, in vitro deposition, and cytotoxicity study. J. Pharm, 795371 : .
Murayama N.,Asai K.,Murayama K.,Doi S. .2019 .Dry powder and budesonide inhalation suspension deposition rates in asthmatic airway-obstruction regions. J. Drug Deliv, 3921426 : .
N. M. Nirale M. S.,Nagarsenker. S. B. Mendon M. S. .2011 .Comparison of aerosol formulations of formoterol fumarate and budesonide. Ind. J. Pharm. Sci., 73(3) : 282-286.
Lewis A.,Torvinen S.,Dekhuijzen P.N.R.,Chrystyn H. .2017 .Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: the potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®. Respir. Med, 129(179) : .
Maruyama S.,Ando S.,Yonemochi E. .2020 .Application of void forming index (VFI): Detection of the effect of physical properties of dry powder inhaler formulations on powder cohesion. Int. J. Pharm., 558(119766) : .
Party P.,Ambrus R. .2023 .Investigation of physicochemical stability and aerodynamic properties of novel "nano-in-micro" structured dry powder inhaler system. Micromachines (Basel), 14(1348) : .
Martin G. P.,Larhrib H.,Ticehurst M. D. .2012 .The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers. Colloids Surf. B. Biointerfaces, 89(29) : .
Noriega-Fernandes M.,Malmlof M.,Nowenwik P.,Gerde P. .2021 .Dry powder inhaler formulation comparison: Study of the role of particle deposition pattern and dissolution. Int. J. Pharm., 607(121025) : .
Jindal S. K.,Pandey K. K.,Bose P. P. .2021 .Dry powder inhalers: particle size and patient-satisfaction. Indian J. Respir. Care, 10(14) : .
H. J. Min E. P.,Stride and Stephen J. Payne E. P. .2023 .In silico investigation of the effect of particle diameter on deposition uniformity in pulmonary drug delivery. Aerosol Sci. Technol, 57(318) : .
Scherließ R.,Bock S.,Bungert N.,Neustock A.,Valentin L. .2022 .Particle engineering in dry powders for inhalation. Eur. J. Pharm. Sci., 172(106158) : .
Groß R.,Berkenfeld K.,Schulte C. .2022 .Effect of texture and surface chemistry on deagglomeration and powder retention in capsule-based dry powder inhaler. AAPS PharmSciTech, 23(281) : .
R. Y. K. Chang H. K.,Chan H. K. .2022 .Advancements in particle engineering for inhalation delivery of small molecules and biotherapeutics. Pharm. Res., 39(3047) : .
A. K. Yazdi and H. D. C. .2016 .Hollow crystalline straws of diclofenac for high-dose and carrier-free dry powder inhaler formulations. Int. J. Pharm., 502(170) : .
T. E. Tarara D. P.,Miller A. E.,Weers A.,Muliadi A. .2022 .Formulation of dry powders for inhalation comprising high doses of a poorly soluble hydrophobic drug. Front. Drug Deliv., 2, (862336) : .
United States Pharmacopeia. USP-NF .2022 .Aerodynamic particle size distribution. , 601 : .
United States Pharmacopeia. USP-NF .2022 .Aerodynamic particle size distribution measurement data for orally inhaled products. , 1604 : .
.2024 .particle-education/understandingand-interpreting-particle-size-distributioncalculations/. (accessed on March 23, : .
International .2005 .Validation of Analytical Procedures: Text and Methodology. , : .
Miyamoto K.,Taga H.,Akita T.,Yamashita C. .2020 .Simple method to measure the aerodynamic size distribution of porous particles generated on lyophilizate for dry powder inhalation. Pharmaceutics, 12(976) : .
Collett J. L.,Murnane D. .2015 .Mathematical approach for understanding deagglomeration behaviour of drug powder in formulations with coarse carrier. Asian J. Pharma. Sci., 10(501) : .
M. .2010 .Minimally-Invasive Drug Delivery Systems for Pharmaceutical and Personal Care Products. Personal Care & Cosmetic Technology, : 209-246.
Wu X.,Miao Z.,Shan Y.,Huang L.,Li L. .2014 .Studies on the spray dried lactose as carrier for dry powder inhalation. Asian J. Pharm. Sci., 9(336) : .
Rahimpour Y.,Hamishehkar H. .2012 .Lactose engineering for better performance in dry powder inhalers. Adv. Pharm. Bull., 2 : 183.
Abiona O.,Wyatt D.,Koner J.,A. Mohammed. J. .2022 .The optimisation of carrier selection in dry powder inhaler formulation and the role of surface energetics. Biomedicines, 10(2707) : .
Zheng Z.,Leung S. S. Y.,Gupta R. .2021 .Flow and particle modelling of dry powder inhalers: methodologies, recent development and emerging applications. Pharmaceutics, 13(189) : .
Shetty N.,Cipolla D.,Park H.,Zhou Q. T. .2020 .Physical stability of dry powder inhaler formulations. Expert Opin, 17 : 77.
Y. B. Wang A. B.,Watts J. I.,Peters S.,Liu A.,Batra R. O. .2014 .Williams III. In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization. AAPS PharmSciTech, 15(981) : .
Zhang Y.,Hubert C. .2022 .Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses. J. Drug Assess, 11(20) : .
M. L. Levy W.,Carroll J. L. I.,Alonso J. L. I. .2019 .Understanding dry powder inhalers: key technical and patient preference attributes. Adv. Ther., 36(2547) : .
Newman. Fine Particle S. P .2022 .Fraction: The Good and the Bad. J. Aerosol Med, 35(2) : .
Negi A.,Nimbkar S.,Moses J. A.,Approaches Emerging .2023 .. , 15(2706) : .
Behara S. R. B.,PW P. W. Longest,Farkas D. R. .2014 .Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations. J. Pharm. Sci., 103(465) : .
D. R. Farkas M.,Hindle P. W.,Longest P. W. .2015 .Characterization of a new high-dose dry powder inhaler (dpi) based on a fluidized bed design. , 43(2804) : .
Mehta P. .2016 .Dry powder inhalers: a focus on advancements in novel drug delivery systems. J. Drug Deliv, 8290963 : .
Lavorini F.,Pistolesi M.,Usmani O. S. .2017 .Recent advances in capsule-based dry powder inhaler technology. Multidiscip. Respir. Med, 12(11) : .
Saldanha S.,Sousa L.,Costa E. .2024 .-formulations-in-drypowder-inhalers-for-high-dose-lung-delivery/. (accessed on March 23, 33 : .
A. H. De Boer P.,Hagedoorn M.,Hoppentocht F.,Buttiniand F. .2017 .Dry powder inhalation: past, present and future. Expert Opin, 14(499) : .
M. D. Louey M. Van,Oort A. J.,Hickey A. J. .2006 .Standardized entrainment tubes for the evaluation of pharmaceutical dry powder dispersion. J. Aerosol Sci., 37(1520) : .
Hagedoorn P.,A. H. de Boer H. W.,Frijlink H. W. .2014 .The clinical relevance of dry powder inhaler performance for drug delivery. Respir. Med, 108(1195) : .
Suzuki E. Y.,Amaro M. I.,Cabral L. M. .2018 .Development of a new formulation of roflumilast for pulmonary drug delivery to treat inflammatory lung conditions. Int. J. Pharm., 550(89) : .
Tan Z. G.,Pandey M.,Srichana T.,Pichika M. R. .2020 .A critical review on emerging trends in dry powder inhaler formulation for the treatment of pulmonary aspergillosis. Pharmaceutics, 12(1161) : .
Lyons N.,Yung D. B. Y.,QuinonesMateu M. E. .2024 .Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections. Eur. J. Pharm. Biopharm., 195(114170) : .
C. J. Musante J. D.,Schroeter J. A.,Rosati T. M.,Crowder T. M. .2002 .Factors affecting the deposition of inhaled porous drug particles. J. Pharm. Sci., 91(1590) : .
Z. M. Tan G. P.,Lai M.,Pandey T.,Srichana T. .2020 .Novel approaches for the treatment of pulmonary tuberculosis. Pharmaceutics, 12(1196) : .
M. Hu J.,Peng K.,Sun D.,Yue D. .2012 .Estimation of size-resolved ambient particle density based on the measurement of aerosol number, mass, and chemical size distributions in the winter in Beijing. Environ. Sci. Technol, 46(9941) : .
Salem Y. A.,Shaldam M. A.,El-Sherbiny D. T.,El-Wasseef D. R.,El-Ashry S. M. .2017 .Simultaneous determination of formoterol fumarate and budesonide epimers in metered dose inhaler using ion-pair chromatography. J. Chromatogr. Sci., 55(1013) : .
Nanasaheb R.,Kale D. A. .2014 .Development and validation of stability indicating rp-hplc method for simultaneous estimation of formoterol fumarate and budesonide in metered dose inhaler formulation. World J. Pharm. Res., 3(1386) : .
Alkhateeb F. L.,Maziarz M.,Rainville P. .2021 .Ultra high-performance liquid chromatography method development for separation of formoterol, budesonide, and related substances using an analytical quality by design approach. J. Pharm. Biomed. Anal., 193(113729) : .
Budesonide .2007 .IP. Ministry of Health and Family welfare. 817-9., 2 : .
United States Pharmacopoeia .2022 .. , : .
United Stated Pharmacopeia .2022 .. , : .
United States Pharmacopeia. USP-NF ,Quality Tests Powders - Performance .2021 .Inhalation and Nasal Drug Products: Aerosols, Sprays, and. , 601 : .
0

Citations

0

Downloads

110

Views